166 related articles for article (PubMed ID: 36352410)
1. Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study.
Jansen EEL; de Kok IMCM; Kaljouw S; Demirel E; de Koning HJ; Hontelez JAC
BMC Med; 2022 Nov; 20(1):433. PubMed ID: 36352410
[TBL] [Abstract][Full Text] [Related]
2. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
3. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
4. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
[TBL] [Abstract][Full Text] [Related]
5. The Differential Risk of Cervical Cancer in HPV-Vaccinated and -Unvaccinated Women: A Mathematical Modeling Study.
Naslazi E; Hontelez JAC; Naber SK; van Ballegooijen M; de Kok IMCM
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):912-919. PubMed ID: 33837119
[TBL] [Abstract][Full Text] [Related]
6. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
7. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
[TBL] [Abstract][Full Text] [Related]
8. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
9. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
10. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
11. Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis.
Portnoy A; Pedersen K; Kim JJ; Burger EA
Br J Cancer; 2024 Jun; 130(12):1951-1959. PubMed ID: 38643338
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
13. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer elimination in Italy: Current scenario and future endeavors for a value based prevention.
Calabrò GE; Riccardi MT; D'Ambrosio F; Castagna C; Sapienza M; Millevolte R; Pellacchia A; Ricciardi R; de Vincenzo RP; de Waure C
Front Public Health; 2022; 10():1010237. PubMed ID: 36530690
[TBL] [Abstract][Full Text] [Related]
15. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
Simms KT; Smith MA; Lew JB; Kitchener HC; Castle PE; Canfell K
Int J Cancer; 2016 Dec; 139(12):2771-2780. PubMed ID: 27541596
[TBL] [Abstract][Full Text] [Related]
16. The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.
Keane A; Ng CW; Simms KT; Nguyen D; Woo YL; Saville M; Canfell K
Int J Cancer; 2021 Dec; 149(12):1997-2009. PubMed ID: 34363620
[TBL] [Abstract][Full Text] [Related]
17. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
Bonanni P; Gabutti G; Demarteau N; Boccalini S; La Torre G
BMC Infect Dis; 2015 Sep; 15():377. PubMed ID: 26381489
[TBL] [Abstract][Full Text] [Related]
19. Strategies to accelerate the elimination of cervical cancer in British Columbia, Canada: a modelling study.
Pataky RE; Izadi-Najafabadi S; Smith LW; Gottschlich A; Ionescu D; Proctor L; Ogilvie GS; Peacock S
CMAJ; 2024 Jun; 196(21):E716-E723. PubMed ID: 38830680
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
